Related Experiment Videos
Magnesium sulphate versus phenytoin for eclampsia
1Resource Centre for Randomised Trials, Institute of Health Sciences, Old Road, Headington, Oxford, UK, OX3 7LF. lelia.duley@ndm.ox.ac.uk
The Cochrane Database of Systematic Reviews
|May 5, 2000
Summary
Magnesium sulfate significantly reduces recurrent seizures in women with eclampsia compared to phenytoin. This anticonvulsant also lowered risks of pneumonia and intensive care unit admissions, benefiting both mothers and newborns.
Area of Science:
- Obstetrics and Gynecology
- Neurology
- Pharmacology
Background:
- Eclamptic seizures pose significant risks to maternal and fetal health.
- Various anticonvulsant medications are employed for seizure control in eclampsia.
Purpose of the Study:
- To compare the efficacy and safety of magnesium sulfate versus phenytoin for treating eclampsia.
- To evaluate the impact of magnesium sulfate on maternal and neonatal outcomes.
Main Methods:
- Systematic review and meta-analysis of randomized controlled trials.
- Included four high-quality trials involving 823 women diagnosed with eclampsia.
- Data extraction and quality assessment performed by two independent reviewers.
Main Results:
- Magnesium sulfate demonstrated a significant reduction in seizure recurrence compared to phenytoin (RR 0.30).
- Maternal mortality trend favored magnesium sulfate, though not statistically significant (RR 0.51).
- Magnesium sulfate use was associated with reduced pneumonia, ventilation needs, and ICU admissions, alongside improved neonatal outcomes including fewer SCBU admissions.
Conclusions:
- Magnesium sulfate is substantially more effective than phenytoin in managing eclampsia.
- The findings support magnesium sulfate as a preferred anticonvulsant for eclampsia treatment.
- Further research may explore comparisons with other agents like diazepam.